LAUNCH OF THE ADVANCE ONLINE COURSE ON ATMPS DEVELOPMENT
EATRIS, along with the ADVANCE consortium partners, is thrilled to announce the launch of the ADVANCE Online Course on ATMPs Development, on December 1st 2020!
WHAT IS ADVANCE?
ADVANCE is a 30-month EU training project, supported by the Erasmus Plus fund. The objective is to develop a 3-stage learning programme to support early-career biomedical scientists in developing currently missing scientific knowledge, transversal skills and competences to meet the key challenge areas existing in the ATMP development cycle.
Earlier in the year, we launched the project with a webinar series that will continue through 2021. All the webinars were recorded and can be watched on–demand on our YouTube Channel and via the ADVANCE Website linked below.
FREE OF CHARGE AND OPEN TO ALL
Our new online course is open to everyone and is completely free of charge. Divided into 4 learning units it represents the key challenges of the ATMPs development cycle: Scientific, Manufacturing, Reimbursement and Regulatory. The self-paced course consists of approximately 7 hours of interactive lectures and nearly 20 hours of independent hands-on and reading assignments.
Through the course participants will hear from 12 experts across academia, industry, regulatory sector and patient organisations discussing the key aspects in the ATMP development pipeline. The lectures are interspersed with questions to help participants stay engaged and think along, and followed by independent assignments to provide an even deeper dive into the content.
12 EXPERTS FROM ACADEMIA, INDUSTRY, REGULATORY AND PATIENT ORGANISATIONS
We would like to thank all our generous experts who contributed their invaluable time and knowledge to put together this exciting curriculum to support the next generation of ATMP developers: Dr. Urban Svajger (Blood Transfusion Center of Slovenia), Dr. Miguel Chillon (Vall d’Hebron Research Institute), Dr. Sebastien Walchli (Oslo University Hospital), Dr. Mangala Srinivas (Radboud University Medical Centre/ Cenya Imaging), Dr. Graziella Pellegrini (University of Modena and Reggio Emilia/ Holostem Terapie Avanzate), Dr. Melissa Van Pel (NECSTGEN), Dr. Cristina Galli (Istituto Superiore di Sanita), Dr. Stephen Sullivan (Global Alliance for iPSC Therapies), Dr. Patrick Celis (European Medicines Agency), Dr. Victoria Palmi Reig European Medicines Agency), Dr. Umberto Restelli (San Raffaele Hospital) and Daniel Kostan (Czech National SMA Patient Organisation – SMACI).